• Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynamics

  2026-05-09

  Mdivi-1 stands out as a selective DRP1 inhibitor, enabling precise modulation of mitochondrial fission and apoptosis in both cell-based and in vivo models. Its robust utility in mitochondrial dynamics research empowers neuroprotection and mechanistic studies of mitochondrial outer membrane permeabilization, making it a critical tool for translational and basic science workflows.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Applied Proteasome Inhibition

  2026-05-09

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) enables reproducible, selective, and reversible proteasome inhibition in both in vitro and in vivo models, making it a top choice for researchers investigating apoptosis, cell cycle regulation, and osteoclast differentiation. This article delivers actionable protocols, troubleshooting strategies, and evidence-based workflow enhancements to maximize the impact of MG-262 in advanced biomedical research.

• Optimizing Hedgehog Pathway Assays with Smoothened Agonist (

  2026-05-08

  This article addresses key challenges in Hedgehog pathway activation assays, focusing on experimental reproducibility, sensitivity, and workflow optimization using Smoothened Agonist (SAG, SKU B5837). By exploring real laboratory scenarios, the discussion demonstrates how SAG provides reliable, literature-backed solutions for cell viability, proliferation, and cytotoxicity studies.

• DiD (DiDC 18 (5)): Raising the Bar in Plasma Membrane Labeli

  2026-05-07

  This thought-leadership article provides translational researchers and advanced cell biologists with mechanistic insights, application strategies, and experimental best practices for leveraging the DiD (DiDC 18 (5)) Plasma Membrane Red Fluorescent Probe. Drawing on recent advances in inflammation research and mitochondrial repair, it situates DiD at the nexus of robust cell membrane labeling, high-throughput cell tracking, and disease modeling—outlining both the product’s unique technical merits and its strategic role in addressing persistent challenges in high-autofluorescence and inflammatory tissue contexts. The article integrates evidence from cutting-edge hydrogel-ROS platforms, showcases protocol recommendations, and directly addresses translational limitations and future opportunities.

• PP2A-Mediated Autophagy Drives Drug Resistance in C. albican

  2026-05-07

  This study reveals that protein phosphatase 2A (PP2A) facilitates autophagy induction via ATG protein phosphorylation, enhancing Candida albicans biofilm formation and drug resistance. These mechanistic insights highlight PP2A and autophagy as targets for overcoming antifungal resistance in clinical fungal infection research.

• Dual TLR2/4 Inhibition Reduces Inflammation in Retinopathy M

  2026-05-06

  This study introduces AVR-123, a novel dual TLR2/4 inhibitor, demonstrating robust anti-inflammatory and anti-angiogenic effects in a mouse model of oxygen-induced retinopathy (OIR). The findings highlight a path to targeted modulation of inflammatory signaling in retinopathy of prematurity, with broader implications for neuroinflammation research.

• AT-406 (SM-406): Optimizing Apoptosis Pathway Activation in

  2026-05-06

  AT-406 (SM-406) empowers cancer researchers with precise, reproducible induction of apoptosis by targeting IAPs, enabling robust analysis in both in vitro and in vivo models. This guide delivers actionable workflow enhancements, troubleshooting insights, and protocol parameters to maximize data quality and experimental success in apoptosis pathway activation studies.

• Paroxetine Mesylate: SSRI Workflows and Oncology Research To

  2026-05-05

  Paroxetine Mesylate offers unique versatility as a selective serotonin reuptake inhibitor with robust kinase inhibitory properties, empowering both neuropsychiatric and oncology research. This article details actionable protocols, experimental optimizations, and troubleshooting strategies for leveraging Paroxetine Mesylate in advanced disease models.

• Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Ther

  2026-05-05

  This study introduces a hyaluronated lipid nanoparticle (HA-LNP) system for transdermal, non-invasive delivery of PTEN tumor suppressor gene mRNA in melanoma models. By restoring PTEN expression and enhancing immune-mediated tumor suppression, the approach addresses immune evasion and checkpoint inhibitor resistance, advancing the field of localized mRNA-based cancer immunotherapy.

• Golgi-Tracker Green: Live-Cell Golgi Labeling for Lipid Path

  2026-05-04

  Golgi-Tracker Green leverages BODIPY FL-labeled C5-ceramide chemistry for precise, photostable Golgi apparatus imaging in live cells. Its superior specificity and workflow reliability make it ideal for unraveling lipid transport and sphingolipid metabolism dynamics, addressing common pain points in real-time organelle research.

• MLN8237 (Alisertib) in Trained Immunity and Tumor Research

  2026-05-04

  Explore how MLN8237 (Alisertib), a selective Aurora A kinase inhibitor, unveils new horizons in trained immunity and cancer biology. This article uniquely bridges epigenetic regulation and anti-tumor strategies, offering insights not found in standard protocol guides.

• Crossbreeding Effects on Xingguo Gray Goose Meat: A Multiomi

  2026-05-03

  This study applies integrated transcriptomic and metabolomic analyses to reveal how crossbreeding and sex influence growth, slaughter performance, and meat quality in Xingguo gray geese. The findings highlight that ternary crossbreeding enhances production traits and alters molecular pathways governing muscle development and lipid metabolism, providing mechanistic insight for genetic improvement strategies.

• HyperScript III RT SuperMix: Elevating Biomarker Analysis in

  2026-05-02

  Discover how HyperScript III RT SuperMix revolutionizes gene expression analysis by enabling high-fidelity cDNA synthesis for challenging colorectal cancer biomarkers. This article uniquely bridges advanced enzymology with recent CRC immunogenomics, offering actionable insights for researchers.

• Adipogenic Transdifferentiation Limits PDAC Metastasis via E

  2026-05-02

  This study demonstrates that enforcing adipogenic transdifferentiation in EMT-high pancreatic ductal adenocarcinoma (PDAC) cells reprograms them into adipocyte-like, post-mitotic cells, significantly reducing metastatic potential. The findings suggest a promising cell-fate conversion strategy for overcoming the limitations of conventional PDAC therapies.

• Sulfo-NHS-SS-Biotin: Protocols for Cleavable Protein Labelin

  2026-05-01

  Sulfo-NHS-SS-Biotin provides a practical solution for specific, reversible labeling of proteins containing primary amines, such as for cell surface protein analysis and affinity purification. It is not suitable for protocols requiring intracellular labeling due to its membrane impermeability, nor for workflows where a non-cleavable tag is necessary.

454 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page